Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996

Article  CAS  PubMed  Google Scholar 

Reardon DA, Brandes AA, Omuro A et al (2020) Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the checkmate 143 phase 3 randomized clinical trial. JAMA Oncol 6:1003–1010

Article  PubMed  Google Scholar 

Duerinck J, Four SD, Bouttens F et al (2017) Randomized phase II trial comparing axitinib with the combination of axitinib and lomustine in patients with recurrent glioblastoma. J Neurooncol 136:115–125

Article  PubMed  Google Scholar 

Awada G, Ben Salama L, De Cremer J et al (2020) Axitinib plus Avelumab in the treatment of recurrent glioblastoma: a stratified, open-label, single-center phase 2 clinical trial (GliAvAx). J Immunother Cancer 8. https://doi.org/10.1136/jitc-2020-001146

Johnson DR, Sawyer AM, Meyers CA et al (2012) Early measures of cognitive function predict survival in patients with newly diagnosed glioblastoma. Neuro Oncol 14:808–816

Article  PubMed  PubMed Central  Google Scholar 

Rogiers A, Leys C, De Cremer J et al (2020) Health-related quality of life, emotional burden, and neurocognitive function in the first generation of metastatic melanoma survivors treated with pembrolizumab: a longitudinal pilot study. Support Care Cancer 28:3267–3278

Article  CAS  PubMed  Google Scholar 

Rogiers A, Leys C, Lauwyck J et al (2020) Neurocognitive function, psychosocial outcome, and health-related quality of life of the first-generation metastatic melanoma survivors treated with ipilimumab. J Immunol Res 2020:2192480

Boele FW, Zant M, Heine ECE et al (2014) The association between cognitive functioning and health-related quality of life in low-grade glioma patients. Neurooncol Pract 1:40–46

PubMed  PubMed Central  Google Scholar 

Coomans M, Dirven L, K Aaronson N et al (2019) The added value of health-related quality of life as a prognostic indicator of overall survival and progression-free survival in glioma patients: a meta-analysis based on individual patient data from randomised controlled trials. Eur J Cancer 116:190–198

Article  PubMed  Google Scholar 

Mauer M, Stupp R, Taphoorn MJB et al (2007) The prognostic value of health-related quality-of-life data in predicting survival in glioblastoma cancer patients: results from an international randomised phase III EORTC brain tumour and radiation oncology groups, and ncic clinical trials group study. Br J Cancer 97:302–307

Article  CAS  PubMed  PubMed Central  Google Scholar 

Meyers CA, Hess KR, Yung WK, Levin VA (2000) Cognitive function as a predictor of survival in patients with recurrent malignant glioma. J Clin Oncol 18:646–650

Article  CAS  PubMed  Google Scholar 

Klein M, Postma TJ, Taphoorn MJB et al (2003) The prognostic value of cognitive functioning in the survival of patients with high-grade glioma. Neurology 61:1796–1798

Article  CAS  PubMed  Google Scholar 

Gorlia T, van den Bent MJ, Hegi ME et al (2008) Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981– 22981/CE.3. Lancet Oncol 9:29–38

Article  PubMed  Google Scholar 

Duerinck J, Schwarze JK, Awada G et al (2021) Intracerebral administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in patients with recurrent glioblastoma: a phase I clinical trial. J Immunother Cancer 9:e002296

Article  PubMed  PubMed Central  Google Scholar 

Okada H, Weller M, Huang R et al (2015) Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol 16:e534–e542

Article  PubMed  PubMed Central  Google Scholar 

Aaronson NK, Ahmedzai S, Bergman B et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376

Article  CAS  PubMed  Google Scholar 

Taphoorn MJB, Claassens L, Aaronson NK et al (2010) An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients. Eur J Cancer 46:1033–1040

Article  PubMed  Google Scholar 

Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A, on behalf of the EORTC Quality of Life Group (2001) The EORTC QLQ-C30 Scoring Manual (3rd Edition)

Field KM, Barnes EH, Sim HW et al (2021) Outcomes from the use of computerized neurocognitive testing in a recurrent glioblastoma clinical trial. J Clin Neurosci 94:321–327

Article  CAS  PubMed  Google Scholar 

Cogstate L (2017) Cogstate pediatric and adult normative data. Cogstate Ltd, New Haven, CT

Google Scholar 

Wefel JS, Vardy J, Ahles T, Schagen SB (2011) International cognition and cancer task force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol 12:703–708

Article  PubMed  Google Scholar 

Spinhoven P, Ormel J, Sloekers PP et al (1997) A validation study of the hospital anxiety and depression scale (HADS) in different groups of Dutch subjects. Psychol Med 27:363–370

Article  CAS  PubMed  Google Scholar 

Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67:361–370

Article  CAS  PubMed  Google Scholar 

Bocéréan C, Dupret E (2014) A validation study of the hospital anxiety and depression scale (HADS) in a large sample of French employees. BMC Psychiatry 14:354

Article  PubMed  PubMed Central  Google Scholar 

Castelli L, Binaschi L, Caldera P et al (2011) Fast screening of depression in cancer patients: the effectiveness of the HADS. Eur J Cancer Care 20:528–533

Article  CAS  Google Scholar 

Stern AF (2014) The hospital anxiety and depression scale. Occup Med 64:393–394

Article  Google Scholar 

Dirven L, Musoro JZ, Coens C et al (2021) Establishing anchor-based minimally important differences for the EORTC QLQ-C30 in glioma patients. Neuro Oncol 23:1327–1336

Article  PubMed  PubMed Central  Google Scholar 

Cocks K, King MT, Velikova G et al (2012) Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. Eur J Cancer 48:1713–1721

Article  CAS  PubMed  Google Scholar 

King MT (1996) The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. Qual Life Res 5:555–567

Article  CAS  PubMed  Google Scholar 

Osoba D, Rodrigues G, Myles J et al (1998) Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16:139–144

Article  CAS  PubMed  Google Scholar 

Giesinger JM, Loth FLC, Aaronson NK et al (2020) Thresholds for clinical importance were established to improve interpretation of the EORTC QLQ-C30 in clinical practice and research. J Clin Epidemiol 118:1–8

Article  PubMed  Google Scholar 

Scherpereel A, Antonia S, Bautista Y et al (2022) First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743. Lung Cancer 167:8–16

Article  CAS  PubMed  Google Scholar 

Larkin J, Chiarion-Sileni V, Gonzalez R et al (2019) Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 381:1535–1546

Article  CAS  PubMed  Google Scholar 

Gonzalez BD, Eisel SL, Bowles KE et al (2022) Meta-analysis of quality of life in cancer patients treated with immune checkpoint inhibitors. J Natl Cancer Inst 114:808–818

Article  PubMed  Google Scholar 

Gilbert MR, Dignam JJ, Armstrong TS et al (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370:699–708

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wefel JS, Armstrong TS, Pugh SL et al (2021) Neurocognitive, symptom, and health-related quality of life outcomes of a randomized trial of bevacizumab for newly diagnosed glioblastoma (NRG/RTOG 0825). Neuro Oncol 23:1125–1138

Article  CAS  PubMed  PubMed Central  Google Scholar 

Montazeri A, Milroy R, Hole D et al (2001) Quality of life in lung cancer patients: as an important prognostic factor. Lung Cancer 31:233–240

Article  CAS  PubMed  Google Scholar 

Troschel FM, Ahndorf F, Wille L-M et al (2021) Quality of life in brain tumor patients and their relatives heavily depends on social support factors during the COVID-19 pandemic. Cancers 13. https://doi.org/10.3390/cancers13061276